Author Archives: Ana Pena, PhD

FDA Grants Orphan Drug Status to Losmapimod as Potential FSHD Therapy

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to losmapimod, an investigational oral therapy for people with facioscapulohumeral muscular dystrophy (FSHD). This designation offers Fulcrum Therapeutics financial support to develop this treatment, as well as a waiver from the FDA’s fees and…